Seres Therapeutics (MCRB) Misses Q1 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. VRTX
4. CRWD
5. CHKP
6. ON
7. HNGE
8. INSP
9. CVI
10. AXSM

Go back to Seres Therapeutics (MCRB) Misses Q1 EPS by 9c

Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

May 4, 2022 7:00 AM EDT

SER-109 open label study results, including safety and efficacy data, including in over 260 individuals enrolled with recurrent C. difficile infection, anticipated in Q2 2022

FDA agreement obtained for rolling SER-109 Biologics License Application (BLA) plan; filing completion on track for mid-2022

SER-109 pre-commercialization activities underway, including medical education and payer engagement

Conference call at 8:30 a.m. ET today

CAMBRIDGE, Mass.--(BUSINESS... More